Table 2.
Comparison of clinical characteristics between the high Ki-67 expression group and low Ki-67 expression group in training and validation groups.
| Variables | Training Group | P | Validation Group | P | ||
|---|---|---|---|---|---|---|
| High Ki-67 | Low Ki-67 | High Ki-67 | Low Ki-67 | |||
| Age(year) | 64.61 ± 12.19 | 64.58 ± 10.49 | 0.992 | 62.16 ± 6.86 | 70.35 ± 10.89 | 0.012* |
| Sex | 0.989 | 0.199 | ||||
| Male | 37 | 29 | 12 | 14 | ||
| Female | 9 | 7 | 7 | 3 | ||
| HBsAg | 0.544 | 0.090 | ||||
| Positive | 29 | 25 | 16 | 10 | ||
| Negative | 17 | 11 | 3 | 7 | ||
| AFP (mg/mL) | 2739.34 ± 12637.85 | 1077.99 ± 5666.61 | 0.471 | 1861.95 ± 6613.78 | 351.69 ± 961.05 | 0.371 |
| Alb (g/L) | 38.5 ± 4.39 | 38.91 ± 4.5 | 0.685 | 38.88 ± 4.83 | 38.8 ± 3.03 | 0.955 |
| ALT(IU/L) | 37.83 ± 26.06 | 47.1 ± 41.67 | 0.227 | 39.25 ± 56.07 | 26.62 ± 17.36 | 0.393 |
| AST(IU/L) | 40.86 ± 24.24 | 49.87 ± 44.26 | 0.25 | 46.75 ± 77.93 | 38.31 ± 21.91 | 0.678 |
| TBIL (µmol/L) |
18.18 ± 22.51 | 17.64 ± 9.48 | 0.893 | 17.41 ± 12.43 | 13.16 ± 5.9 | 0.22 |
| DBIL (µmol/L) |
6.58 ± 13.31 | 6.35 ± 4.79 | 0.924 | 5.22 ± 4.0 | 5.62 ± 5.63 | 0.81 |
| PT (s) | 12.97 ± 1.14 | 13.33 ± 1.33 | 0.196 | 13.44 ± 1.9 | 12.84 ± 1.29 | 0.289 |
| INR | ||||||
| Tumor Size (cm) |
1.04 ± 0.1 | 1.06 ± 0.11 | 0.306 | 1.07 ± 0.2 | 1.05 ± 0.09 | 0.68 |
| Cirrhosis | 0.696 | 0.158 | ||||
| Absent | 21 | 18 | 9 | 12 | ||
| Present | 25 | 18 | 10 | 5 | ||
| Multifocality | 0.362 | 0.797 | ||||
| Absent | 36 | 31 | 15 | 14 | ||
| Present | 10 | 5 | 4 | 4 | ||
AFP, alpha fetoprotein; ALB, albumin level; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; DBIL, directed bilirubin; PT, prothrombin time; INR, international normalized ratio.